Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin effects on cardiac deformation and outcomes in non-diabetic heart failure with reduced or mildly reduced ejection fraction
2021-005394-66Phase 4Completed
- Sponsor
- Azienda Ospedaliera Universitaria Senese
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of dapagliflozin in heart failure (HF), heart failure with reduced ejection fraction (HFrEF), heart failure with mid-range ejection fraction (HFmrEF) and 1 more (2 arms), sponsored by Azienda Ospedaliera Universitaria Senese. Primary endpoint: Change in left ventricular myocardial performance. Started Nov 2021; status: completed.
02
Drugs
dapagliflozin
03
Conditions
heart failure (HF)heart failure with reduced ejection fraction (HFrEF)heart failure with mid-range ejection fraction (HFmrEF)left ventricular systolic dysfunction (LVSD)
Beyond the preview
Go deeper on 2021-005394-66.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005394-66.